Skating to where the puck is going to be: A plan for clinical trials and translation research in mood disorders

被引:14
作者
Frank, E
Rush, AJ
Blehar, M
Essock, S
Hargreaves, W
Hogan, M
Jarrett, R
Johnson, RL
Katon, WJ
Lavori, P
McNulty, JP
Niederehe, G
Ryan, N
Stuart, G
Thomas, SB
Tollefson, GD
Vitiello, B
机构
[1] Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA
[2] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA
[3] NIMH, Bethesda, MD 20892 USA
[4] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA
[5] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA
[6] Ohio Dept Mental Hlth, Columbus, OH USA
[7] New Jersey Med Ctr, Dept Pediat, Newark, NJ USA
[8] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[9] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA
[10] Natl Man Depress & Depress Assoc Rhode Isl, Providence, RI USA
[11] Med Univ S Carolina, Coll Nursing & Med, Charleston, SC 29425 USA
[12] Univ Pittsburgh, Dept Community Hlth & Socail Justice, Pittsburgh, PA USA
[13] Eli Lilly & Co, Neurosci Prod, Indianapolis, IN 46285 USA
关键词
clinical trials; translation research; mood disorders;
D O I
10.1016/S0006-3223(02)01467-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
As part of the National Institute of Mental Health Strategic Plan for Mood Disorders Research effort, the Clinical Trials and Translation Workgroup was asked to define priorities for clinical trials in mood disorders and for research on how best to translate the results of such research to clinical practice settings. Through two face-to-face meetings and a series of conference calls, we established priorities based on the literature to date and what was known about research currently in progress in this area. We defined five areas of priority that cut across developmental stages, while noting that research on adult mood disorders was at a more advanced stage in each of these areas than research on child or geriatric disorders. The five areas of priority are: 1) maximizing the effectiveness and cost-effectiveness of initial (acute) treatments for mood disorders already known to be efficacious in selected populations and settings when they are applied across all populations and care settings; 2) learning what further treatments or services are most likely to reduce symptoms and improve functioning when the first treatment is delivered well, but the mood disorder does not remit or show adequate improvement; 3) learning what treatments or services are most cost-effective in preventing recurrence or relapse and maintaining optimal functioning after a patient's mood disorder has remitted or responded maximally to treatment; 4) developing and validating clinical, psychosocial, biological, or other markers that predict: a) which treatments are most effective, b) course of illness, c) risk of adverse events/tolerability and acceptability for individual patients or well-defined subgroups of patients; 5) developing clinical trial designs and methods that result in lower research costs and greater generalizability earlier in the treatment development and testing process. A rationale for the importance of each of these priorities is provided.
引用
收藏
页码:631 / 654
页数:24
相关论文
共 168 条
[1]  
Agency for Health Care Policy and Research, 1993, DEPR PRIM CAR, V2
[2]   Estrogen deficiency in severe postpartum depression:: Successful treatment with sublingual physiologic 17β-estradiol:: A preliminary study [J].
Ahokas, A ;
Kaukoranta, J ;
Wahlbeck, K ;
Aito, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (05) :332-336
[3]   Positive treatment effect of estradiol in postpartum psychosis:: A pilot study [J].
Ahokas, A ;
Aito, M ;
Rimón, R .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (03) :166-169
[4]  
Akiskal H. S., 1997, Dysthymia and the spectrum of chronic depressions
[5]   A review of pharmacotherapy of major depression in children and adolescents [J].
Ambrosini, PJ .
PSYCHIATRIC SERVICES, 2000, 51 (05) :627-633
[6]  
Angold A, 1999, J CHILD PSYCHOL PSYC, V40, P57, DOI 10.1111/1469-7610.00424
[7]  
[Anonymous], DEPR PRIM CAR
[8]   A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression [J].
Appleby, L ;
Warner, R ;
Whitton, A ;
Faragher, B .
BRITISH MEDICAL JOURNAL, 1997, 314 (7085) :932-936
[9]   COMPARATIVE EFFECTIVENESS OF SOCIAL PROBLEM-SOLVING THERAPY AND REMINISCENCE THERAPY AS TREATMENTS FOR DEPRESSION IN OLDER ADULTS [J].
AREAN, PA ;
PERRI, MG ;
NEZU, AM ;
SCHEIN, RL ;
CHRISTOPHER, F ;
JOSEPH, TX .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1993, 61 (06) :1003-1010
[10]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95